These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 3929296

  • 1. Serotonergic potentiation of muscarinic agonist evoked tremor and salivation in rat and mouse.
    Ogren SO, Carlsson S, Bartfai T.
    Psychopharmacology (Berl); 1985; 86(3):258-64. PubMed ID: 3929296
    [Abstract] [Full Text] [Related]

  • 2. In vivo and in vitro studies on the potentiation of muscarinic receptor stimulation by alaproclate, a selective 5-HT uptake blocker.
    Ogren SO, Nordström O, Danielsson E, Peterson LL, Bartfai T.
    J Neural Transm; 1985; 61(1-2):1-20. PubMed ID: 2984330
    [Abstract] [Full Text] [Related]

  • 3. GEA 857, a putative blocker of potassium conductance, enhances muscarinic agonist-evoked responses: dissociation from an action on 5-HT mechanisms.
    Ogren SO, Bartfai T, Hedlund B, Lindberg UH.
    Pharmacol Toxicol; 1992 Aug; 71(2):112-9. PubMed ID: 1438027
    [Abstract] [Full Text] [Related]

  • 4. Evidence for a possible functional interaction between serotonergic and cholinergic mechanisms in memory retrieval.
    Altman HJ, Stone WS, Ogren SO.
    Behav Neural Biol; 1987 Jul; 48(1):49-62. PubMed ID: 3632552
    [Abstract] [Full Text] [Related]

  • 5. Nonmuscarinic neurotoxicity of oxotremorine.
    Witkin JM, Alvarado-Garcia R, Lee MA, Witkin KM.
    J Pharmacol Exp Ther; 1987 Apr; 241(1):34-41. PubMed ID: 3572794
    [Abstract] [Full Text] [Related]

  • 6. BM-5, a centrally active partial muscarinic agonist with low tremorogenic activity. In vivo and in vitro studies.
    Engström C, Undén A, Ladinsky H, Consolo S, Bartfai T.
    Psychopharmacology (Berl); 1987 Apr; 91(2):161-7. PubMed ID: 3107028
    [Abstract] [Full Text] [Related]

  • 7. In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine.
    Howell G, West L, Jenkins C, Lineberry B, Yokum D, Rockhold R.
    BMC Pharmacol; 2005 Aug 18; 5():13. PubMed ID: 16109168
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Modification of oxotremorine tremor and hypothermia by injections of drugs into the cerebral ventricles of the mouse.
    Doggett NS, O'Farrell SA.
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug 18; 294(2):149-55. PubMed ID: 1012335
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazaspiro-[4,5]-decan-1,3-dion hydrobromide). A potent, specific muscarinic acetylcholine receptor agonist.
    Palacios JM, Bolliger G, Closse A, Enz A, Gmelin G, Malanowski J.
    Eur J Pharmacol; 1986 Jun 05; 125(1):45-62. PubMed ID: 3732391
    [Abstract] [Full Text] [Related]

  • 16. Downregulation of muscarinic- and 5-HT1B-mediated modulation of [3H]acetylcholine release in hippocampal slices of rats with fimbria-fornix lesions and intrahippocampal grafts of septal origin.
    Cassel JC, Jeltsch H, Neufang B, Lauth D, Szabo B, Jackisch R.
    Brain Res; 1995 Dec 18; 704(2):153-66. PubMed ID: 8788910
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.